|Day's Range||81.20 - 82.25|
|52 Week Range||64.18 - 86.72|
|PE Ratio (TTM)||39.66|
|Dividend & Yield||2.08 (2.57%)|
|1y Target Est||N/A|
Q1 2017 Eli Lilly and Co Earnings Call
Eli Lilly & Co.'s (LLY) new products include Cyramza, Basaglar, Jardiance, and Lartruvo.
The growth for Eli Lilly's Human Pharmaceuticals segment, which contributes ~85.3% to its total revenues, was driven by increased sales of products such as Trulicity, Humalog, and Cyramza.